1st Quarter - Report

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Firm
Client
Income
—
Expenses
$4,680,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

H.R. 3167, Playing Fair on Trade and Innovation Act: Provisions related to intellectual property H.R. 3830, Bipartisan Congressional Trade Priorities Act of 2014: Provisions related to trade agreements S. 1900, Bipartisan Congressional Trade Priorities Act of 2014: Trade promotion authority issues Korea Free Trade Agreement: Implementation issues related to intellectual property, market access and public healthTrans-Pacific Partnership (TPP): Provisions related to intellectual property, market access and public health issues Mexico and Canada IP and market access issues Turkey Market Access Issues India innovation, IP and market access issues Transatlantic Trade and Investment Partnership (TTIP): Market access, intellectual property, regulatory and other issues The Agriculture Reform, Food and Jobs Act of 2013/H.R. 1947, Federal Agriculture Reform and Risk Management Act of 2013: Issues related to World Trade Organization (WTO) Brazil Cotton dispute Issues related to Special 301 and National Trade Estimate (NTE) submissions including intellectual property and market access issues China intellectual property and market access issues International market access and intellectual property issues Biopharmaceutical innovation policy issues Trade Promotion Authority policy issues Generalized System of Preferences policy issues

LobbyistCovered position, as disclosed
JOHN J CASTELLANI —
CHESTER (CHIP) DAVIS —
LEO FARBER —
LEA FISHER —
JEFFREY FRANCER —
DAVID KORN —
COLLEEN MALONEY —
CARA MOON —
ANNE PRITCHETT —
JAMES M SPEARS —

Contacted: Patent & Trademark Office (PTO); Natl Security Council (NSC); White House Office; Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); SENATE; U.S. Trade Representative (USTR); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; State, Dept of (DOS); Executive Office of the President (EOP)

Bills named: S. 1900 (113th), H.R. 1947 (113th), H.R. 3167 (113th), H.R. 3830 (113th)

Health Issues HCR

H.R. 3742, Antibiotic Development to Advance Patient Treatment Act of 2013: Provisions related to antibiotics and drug approval H.R. 4069, Ensuring Patient Access and Effective Drug Enforcement Act of 2013: Provisions related to the Controlled Substances Act, DEA regulation and related issuesS. 264, Excellence in Mental Health Act: Sets forth criteria for the certification of federally-qualified community behavioral health centers S. 1699, Prescription Drug Cost Reduction Act: Provisions related to 340B (112th Congress) S. 957, Drug Supply Chain Security Act: Provisions related to supply chain security S. 959, Pharmaceutical Quality, Security, and Accountability Act: Provisions related to pharmaceutical compounding S. 1723, No ObamaCare Kickbacks Act of 2013: Provisions related to application of the anti-kickback statute to qualified health plans S. 2295, Patient Safety and Generic Labeling Improvement Act: Provisions relating to drug safety labeling (112th Congress) Implementation issues related to the Food and Drug Administration Safety and Innovation Act (Public Law 112-144), including user fee reauthorization and FDA reform Implementation issues related to the Drug Quality and Security Act (Public Law 113-54), including pharmacy compounding and supply chain issues Implementation issues related to the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), including PPACA; Standards Related to Essential Health Benefits, Actuarial Value, and Accreditation rulemaking Issues related to user fee reauthorization and FDA reform Patient savings program policy issues Comparative effectiveness policy issues Academic detailing policy issues General HHS and FDA related advocacy Biopharmaceutical innovation policy issues Prescription drug abuse policy issues FDA accelerated approval policy issues Unapproved use policy issues 340B policy issues Importation policy issues Clinical trial policy issues

LobbyistCovered position, as disclosed
MAYA BERMINGHAM —
RANDY BURKHOLDER —
JOHN J CASTELLANI —
CHARLES M. CLAPTON New Leg. Aide - Senate Judiciary Comm.; Senior, Leg. Aide and Counsel - Rep. Harris Fawell;, Oversight Counsel - House Energy &, Commerce Comm. (E&C); Health Counsel -, E&C; Chief Health Counsel - E&C; Health, Policy Advisor - Speaker Dennis Hastert, Chief Health Counsel - House Ways Means, Comm.; Health Policy Director - Senate HELP, Comm.
CHESTER (CHIP) DAVIS —
LEO FARBER —
LEA FISHER —
PETER FOTOS —
JEFFREY FRANCER —
SASCHA HAVERFIELD-GROSS —
VALERIE HARDIN JEWETT —
LISA JOLDERSMA New Not applicable
COLLEEN MALONEY —
CARA MOON —
ANNE PRITCHETT —
LORI REILLY —
JENNIFER ROMANS —
NICK SHIPLEY —
JAMES M SPEARS —
MATTHEW L SULKALA —

Contacted: Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); Patent & Trademark Office (PTO); State, Dept of (DOS); Natl Security Council (NSC); U.S. Trade Representative (USTR); Food & Drug Administration (FDA); White House Office; SENATE

Bills named: S. 959 (113th), S. 2295 (113th), S. 1699 (113th), S. 1723 (113th), H.R. 4069 (113th), S. 957 (113th), H.R. 3742 (113th)

Medicare/Medicaid MMM

H.R. 351, Protecting Seniors Access to Medicare Act of 2013: Provisions related to the Independent Payment Advisory Board H.R. 928, Medicare Prescription Drug Savings and Choice Act of 2013: Provisions related to Part D issues H.R. 1024, Medication Therapy Management Empowerment Act of 2013: Provisions related to medication therapy management in Part DH.R. 1102, Medicare Prescription Drug Price Negotiation Act of 2013: Provisions related to Part D issues and non-interference H.R. 1588, Medicare Drug Savings Act of 2013: Provisions related to Part D issues H.R. 2810, Medicare Patient Access and Quality Improvement Act: Provisions related to SGR reform H.R. 2827, Part D Beneficiary Appeals Fairness Act: Provisions related to the specialty tier in Part D H.R. 2925, Strengthening Medicare Anti-Fraud Measures Act of 2013: Provisions related to fraud and abuse H.R. 3392, Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013: Provisions related to lock-in programs H.R. 3796, Comprehensive Care Payment Innovation Act: Provisions related to alternative payment models H.R. 4160, Keep the Promise to Seniors Act of 2014: Provisions related to Part D issues H.R. 4302, Protecting Access to Medicare Act of 2014: Provisions related to the biopharmaceutical industry S. 117, Medicare Prescription Drug Price Negotiation Act of 2013: Provisions related to Part D issues and non-interference S. 351, Protecting Seniors Access to Medicare Act of 2013: Provisions related to Independent Payment Advisory Board S. 408, Medicare Prescription Drug Savings and Choice Act of 2013: Provision related to Part D issues S. 740, Medicare Drug Savings Act of 2013: Provisions related to Part D issues Deficit reduction policy issues S. 882, Stop Trafficking of Pills (STOP) Act: Provisions related to lock-in programs (112th Congress) S. 1365, Part D Beneficiary Appeals Fairness Act: Provisions related to the specialty tier in Part D S. 1871, SGR Repeal and Medicare Beneficiary Access Act of 2013: Provisions related to reforming Medicare physician payments S. 1932, Better Care, Lower Cost Act: Provisions related to Part D, value-based insurance design, and chronic disease S. 2000, SGR Repeal and Medicare Provider Payment Modernization Act of 2014: Provisions related to SGR reform S. 2110, Medicare SGR Repeal and Beneficiary Access Improvement Act of 2014: Provisions related to SGR reform Medicare Prescription Drug Diversion and Abuse Prevention Act: Provisions related to diversion and abuse (no bill number) Contract Year 2015 Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefits Programs: Provisions related to Part D Proposals to increase co-payments for Part D beneficiaries receiving the low-income subsidy Medicaid Program, Covered Outpatient Drugs rulemaking Medicare sustainable growth rate policy issues Implementation issues relating to the Physician Payment Sunshine Act, including Medicare, Medicaid, Childrens Health Insurance Programs; Transparency Reports and Reporting of Physician Ownership or Investment Interests rulemaking

LobbyistCovered position, as disclosed
MAYA BERMINGHAM —
RANDY BURKHOLDER —
JOHN J CASTELLANI —
CHARLES M. CLAPTON New Leg. Aide - Sen. Judiciary Comm.; Senior Leg., Aide and Counsel - Rep. Harris Fawell;, Oversight Counsel - House Energy &, Comm. (E&C); Health Counsel - E&C; Chief, Health Counsel - E&C; Health Policy Advisor -, Speaker Dennis Hastert; Chief Health Counsel -, House Ways Means Comm.; Health Policy, Director - Senate HELP Comm.
CHESTER (CHIP) DAVIS —
LEA FISHER —
PETER FOTOS —
VALERIE HARDIN JEWETT —
LISA JOLDERSMA New Not applicable
COLLEEN MALONEY —
CARA MOON —
LORI REILLY —
JENNIFER ROMANS —
NICK SHIPLEY —
JAMES M SPEARS —
MATTHEW L SULKALA —

Contacted: Commerce, Dept of (DOC); Natl Security Council (NSC); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Patent & Trademark Office (PTO); U.S. Trade Representative (USTR); Executive Office of the President (EOP); State, Dept of (DOS); SENATE; HOUSE OF REPRESENTATIVES; White House Office

Bills named: H.R. 2925 (113th), H.R. 1588 (113th), H.R. 4160 (113th), H.R. 3796 (113th), S. 2110 (113th), H.R. 2810 (113th), H.R. 928 (113th), H.R. 3392 (113th), S. 1365 (113th), S. 117 (113th), S. 882 (113th), S. 1871 (113th), S. 351 (113th), H.R. 351 (113th), H.R. 1024 (113th), S. 2000 (113th), H.R. 2827 (113th), S. 408 (113th), S. 740 (113th), H.R. 4302 (113th), S. 1932 (113th)

Copyright/Patent/Trademark CPT

H.R. 22, Foreign Counterfeit Merchandise Prevention Act: Provisions related to counterfeiting H.R. 845, Saving High-Tech Innovators from Egregious Legal Disputes Act of 2013 (the SHIELD Act): Provisions related to patent litigation H.R. 2024, End Anonymous Patents Act: Patent owner information provisionsH.R. 2582, PATENT Jobs Act: Provisions related to patent user fees H.R. 2605, Manufacturing Innovation in America Act of 2013: Provisions related to patent tax boxes H.R. 2639, Patent Litigation and Innovation Act: Patent litigation proposals H.R. 2766, STOP Act: Provisions related to business method patents H.R. 2985, Combination Drug Development Incentive Act of 2013 H.R. 3116, MODDERN Cures Act of 2013 H.R. 3309, Innovation Act: Provisions related to patent litigation reform H.R. 3349, Innovation Protection Act: PTO Fee Diversion H.R. 3540, Demand Letter Transparency Act of 2013: Provisions related to patent demand letters H.R. 3709, Protecting Consumer Access to Generic Drugs Act of 2013: Provisions related to patent settlements H.R. 4287, Independent Innovator and Repurposing Act: Provisions related to patent term restoration S. 214, Preserve Access to Affordable Generics Act: Provisions related to patent settlements S. 504, Fair and Immediate Release of Generic Drugs Act: Provisions related to patent settlements S. 626, Prize Fund for HIV/AIDS Act: Medical prize provisions S. 627, Medical Innovation Prize Fund Act: Medical prize provisions S. 712, Patents for Humanity Program Improvement Act of 2013: Transferability of PTO vouchers provisions S. 866, Patent Quality Improvement Act of 2013: Business methods patents provisions S. 1013, Patent Abuse Reduction Act of 2013: Patent litigation provisions S. 1612, Patent Litigation Integrity Act of 2013: Patent litigation provisions including bonding S. 1720, Patent Transparency and Improvements Act of 2013: Provisions related to patent litigation, demand letters and the patent system S, 2049, Transparency in Assertion of Patents Act: Provisions related to patent demand letters S. 2150, Independent Innovator and Repurposing Act: Provisions related to patent term restoration S. 2146, Patent Fee Integrity Act: Patent fee diversion prohibition Biopharmaceutical innovation policy issues Biologics data protection issues Draft legislation on trade secret issues

LobbyistCovered position, as disclosed
JOHN J CASTELLANI —
CHARLES M. CLAPTON New Leg. Aide - Sen. Judiciary Comm.; Senior Leg., Aide and Counsel - Rep. Harris Fawell;, Oversight Counsel - House Energy and, Commerce Comm. (E&C); Health Counsel -, E&C; Chief Health Counsel - E&C; Health, Policy Advisor - Speaker Dennis Hastert; Chief, Health Counsel - House Ways Means Comm.;, Health Policy Director - Senate HELP Comm.
CHESTER (CHIP) DAVIS —
LEO FARBER —
LEA FISHER —
PETER FOTOS —
VALERIE HARDIN JEWETT —
DAVID KORN —
COLLEEN MALONEY —
CARA MOON —
ANNE PRITCHETT —
JENNIFER ROMANS —
JAMES M SPEARS —
MATTHEW L SULKALA —

Contacted: Natl Security Council (NSC); State, Dept of (DOS); Food & Drug Administration (FDA); SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); White House Office; U.S. Trade Representative (USTR); Executive Office of the President (EOP); Patent & Trademark Office (PTO)

Bills named: S. 1612 (113th), H.R. 3309 (113th), H.R. 3116 (113th), S. 2146 (113th), H.R. 3709 (113th), S. 2150 (113th), S. 504 (113th), H.R. 845 (113th), S. 712 (113th), S. 866 (113th), S. 626 (113th), S. 627 (113th), H.R. 2766 (113th), H.R. 22 (113th), H.R. 3540 (113th), H.R. 4287 (113th), S. 214 (113th), H.R. 2605 (113th), H.R. 2985 (113th), S. 1720 (113th), H.R. 2024 (113th), H.R. 3349 (113th), S. 1013 (113th), H.R. 2639 (113th)

Budget/Appropriations BUD

FY 2015 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act: Provisions related to Food and Drug Administration (FDA) regulation and funding, sequestration, drug importation (no bill number) Implementation issues related to the Food and Drug Administration Safety and Innovation Act (Public Law 112-144), including user fee reauthorization and FDA reformFY 2015 Commerce, Justice, Science, and Related Agencies Appropriations Act: Provisions related to trade and prescription narcotics regulation (no bill number) FY 2015 Department of Homeland Security Appropriations Act: Provisions related to Customs and Border Control Agency funding, drug imports (no bill number) FY 2015 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act: Provisions related to 340B Drug Pricing Program, National Institutes of Health (NIH), Independent Payment Advisory Board (IPAB), Agency for Healthcare Research & Quality (AHQR) (no bill number) H.R. 3547, Consolidated Appropriations Act, 2014: Provisions related to FDA regulation and funding, sequestration, drug importation, trade and prescription narcotics regulation, Customs and Border Control Agency funding, 340B, NIH, IPAB and AHQR Issues related to user fee reauthorization and FDA reform

Contacted: Commerce, Dept of (DOC); White House Office; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Executive Office of the President (EOP); SENATE; Patent & Trademark Office (PTO); Natl Security Council (NSC); State, Dept of (DOS); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR)

Bills named: H.R. 3547 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.